Can-Fite BioPharma Full Year 2024 Earnings: US$0.004 loss per share (vs US$0.006 loss in FY 2023)

Simply Wall St · 2d ago

Can-Fite BioPharma (TLV:CANF) Full Year 2024 Results

Key Financial Results

  • Net loss: US$7.88m (loss widened by 3.2% from FY 2023).
  • US$0.004 loss per share.
We've discovered 4 warning signs about Can-Fite BioPharma. View them for free.
earnings-and-revenue-growth
TASE:CANF Earnings and Revenue Growth April 16th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Can-Fite BioPharma Earnings Insights

Looking ahead, revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Asia.

Performance of the market in Israel.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Can-Fite BioPharma (3 make us uncomfortable!) that we have uncovered.